PT UBC Medical Indonesia Tbk (LABS) Fair Value & Analysis
Healthcare · ID · Market cap 585B IDR
Fair value as of: Jul 11, 2026
From 24 valuation models · updated 30 days ago
Share price +6.1% over the past month.
Below-average quality, and screening another 52% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (93.53 IDR). The favourable scenario is already priced in.
- Solid but not exceptional quality (47/100) and above fair value, neither a clear bargain nor a standout compounder.
- A fairly wide model range (50.23 IDR to 93.53 IDR) leaves room in how you read the outcome.
Price vs Fair Value (2 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 11, 2026.
How to read this chart
25‑month range 109.00 IDR – 216.00 IDR · fair‑value band 50.23 IDR – 93.53 IDR · the 157.00 IDR price screens above the 76.01 IDR fair value. Dashed = 300-day average. As of Jul 11, 2026.
Analysis
PT UBC Medical Indonesia Tbk (LABS) currently trades at 157.00 IDR, while our model-based Fair Value estimate is 76.01 IDR, implying the stock looks roughly 51.6% overvalued today. The Quality Score stands at 47/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, PT UBC Medical Indonesia Tbk generated revenue of 206B IDR at a net margin of 5.9%. Revenue grew 19.6% year over year. It earns a return on equity of 8.2%. The balance sheet holds a net cash position of 13.7B IDR. Fundamentals as of Jul 11, 2026
Our scenario range runs from 50.23 IDR (bear case) to 93.53 IDR (bull case); at 157.00 IDR, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 40% below its 52-week high and 31% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -26% fair-value upside, at -52%, LABS screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 24 models by family
Widest divergence: DCF Models (133.49 IDR) versus Asset-Based (25.86 IDR). Highest evidence: Growth DCF (80).
Notify me when LABS reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 11, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 50 · Market factors (momentum, volatility) 37
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
PT UBC Medical Indonesia Tbk engages in the marketing and distribution of medical devices in Indonesia. The company operates in two segments, Medical Disposables and Consumables, and Diagnostics and Equipment.
Full company description
PT UBC Medical Indonesia Tbk engages in the marketing and distribution of medical devices in Indonesia. The company operates in two segments, Medical Disposables and Consumables, and Diagnostics and Equipment. It offers TB management, newborn screening, HPV DNA test, real time PCR, infectious disease, extraction kit, all-in-one GP workstation, hisky, and AIRDOC products. The company also wholesale of laboratory equipment, pharmaceutical equipment, and medical equipment for human beings and animals; and chemical products and traditional medicine. The company was founded in 2014 and is based in Jakarta Timur, Jakarta. PT UBC Medical Indonesia Tbk operates as a subsidiary of PT Optel Investama Mulia.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
PT UBC Medical Indonesia Tbk reported revenue of 199B IDR in FY2025 versus 130B IDR in FY2021, a compound +11.3%/yr. Reported net income was 13.5B IDR in FY2025, compounding +157.3%/yr from FY2021.
LABS screens 52% overvalued. Compare with Abbott Laboratories, →
Peer Group
Medical Devices · 352 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Devices median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jul 11, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | $100.68 | $74.79 | -26% |
| Stryker Corporation SYK | $316.44 | $186.28 | -41% |
| Medtronic plc MDT | $83.56 | $65.57 | -22% |
| Boston Scientific Corporation BSX | $43.04 | $38.44 | -11% |
| Edwards Lifesciences Corporation EW | $85.73 | $41.02 | -52% |
| Siemens Healthineers AG SHL | €34.59 | €33.87 | -2% |
| DexCom, Inc DXCM | $74.96 | $38.95 | -48% |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥149.43 | ¥147.63 | -1% |
| Shanghai United Imaging Healthcare Co 688271 | ¥109.00 | ¥43.60 | -60% |
| Demant A/S DEMANT | kr 276.60 | kr 161.17 | -42% |
Compare PT UBC Medical Indonesia Tbk with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is PT UBC Medical Indonesia Tbk (LABS) overvalued or undervalued?
What is the fair value of LABS?
What is the quality score of LABS?
What is the revenue of PT UBC Medical Indonesia Tbk (LABS)?
What is the net profit margin of LABS?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track PT UBC Medical Indonesia Tbk and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.